Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Potential therapeutic effects of natural extracts in multiple myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy characterized by proliferation of monoclonal plasmas cells in bone marrow. Despite the advent of new agents targeting the neoplastic clone and its microenvironment, MM is still to be hard-to-treat cancer, with patients experiencing subsequent phases of remission and relapse, eventually leading to therapies resistance and pat...
متن کاملIdentification of potential glucocorticoid receptor therapeutic targets in multiple myeloma
Glucocorticoids (GC) are a cornerstone of combination therapies for multiple myeloma. However, patients ultimately develop resistance to GCs frequently based on decreased glucocorticoid receptor (GR) expression. An understanding of the direct targets of GC actions, which induce cell death, is expected to culminate in potential therapeutic strategies for inducing cell death by regulating downstr...
متن کاملThe therapeutic potential of cell cycle targeting in multiple myeloma
Proper cell cycle progression through the interphase and mitosis is regulated by coordinated activation of important cell cycle proteins (including cyclin-dependent kinases and mitotic kinases) and several checkpoint pathways. Aberrant activity of these cell cycle proteins and checkpoint pathways results in deregulation of cell cycle progression, which is one of the key hallmarks of cancer. Con...
متن کاملProteasome inhibition and its therapeutic potential in multiple myeloma
Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an unprecedented eight years. In the wake of this rapid approval arose a large number of questions about its mechanism of action and toxicity as well as its ultimate role in the treatment of this disease. In this article, we briefly r...
متن کاملp53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instanc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2021
ISSN: 1718-7729
DOI: 10.3390/curroncol28030193